Seda S. Tolu MD
Assistant Professor, Columbia University Irving Medical Center, New York, New YorkSeda S. Tolu, MD, is an Assistant Professor of Medicine in the Division of Hematology and Oncology, Center for Lymphoid Malignancies, at the Herbert Irving Comprehensive Cancer Center of Columbia University Irving Medical Center.
Dr. Tolu earned her undergraduate degree in Neurobiology & Physiology at University of Maryland followed by her Medical Doctorate from University of Maryland, Baltimore. She completed her Internal Medicine residency at Montefiore Medical Center/Albert Einstein College Medicine where she had the honor of serving as Chief Resident. Dr. Tolu then went on to complete her fellowship in Hematology & Oncology at Columbia University Irving Medical Center, where she also served as Chief Fellow.
Throughout her career, Dr. Tolu has earned several awards and scholarships for her research and academic achievements including the Howard Hughes Medical Institute (HHMI)/National Institutes of Health (NIH) Research Scholarship, the Research Training Award for Fellows (RTAF), the Conquer Cancer Foundation Young Investigator Award (YIA), and the Cutaneous Lymphoma Foundation (CLF) YIA. She was also selected to participate in the prestigious American Association for Cancer Research (AACR)/Molecular Biology in Clinical Oncology Workshop, the American Society of Hematology (ASH)/Clinical Research Training Institute (CRTI), the Academy of Next Wave of Clinical Investigators in Non-Hodgkin’s Lymphoma, and the Food & Drug Administration (FDA)/American Society of Clinical Oncology (ASCO) Fellows Workshop. She continues to serve as a member of the Alpha Omega Alpha (AOA) Honor’s Society.
Dr. Tolu’s pre-clinical research focuses on identifying synergistic targeted therapies using novel methods to accurately recapitulate lymphoma biology. As a clinical investigator, Dr. Tolu leads multi-center retrospective collaborative studies focusing on outcomes research in Peripheral T-cell Lymphoma. She is highly involved in numerous clinical trials at Columbia spanning across Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Peripheral T-cell Lymphomas, and Cutaneous T-cell Lymphomas.
Disclosures
Dr. Tolu has no relevant disclosures.Recent Contributions to PracticeUpdate:
- Valemetostat for Relapsed or Refractory Peripheral T-Cell Lymphoma
- Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone Followed by Brentuximab Vedotin Consolidation for CD30-Positive Peripheral T-Cell Lymphomas
- Combination Targeted Therapy for Relapsed Diffuse Large B-Cell Lymphoma